Atossa Therapeutics Inc. (ATOS) NASDAQ
$1.53 - (-)
Market Cap: $191.72M
As of 04/29/24 03:59 PM EDT. Market closed.
Atossa Therapeutics Inc. (ATOS)
NASDAQ
$1.53
- (-)
Market Cap: $191.72M
As of 04/29/24 03:59 PM EDT. Market closed.
Add to Portfolio
atossa therapeutics, inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the united states. the company's lead program is the development of endoxifen, an active metabolite of tamoxifen which is in phase ii studies to treat and prevent breast cancer. it is also developing intraductal microcatheter technology to target the delivery ... read more
COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Steven Quay
Address
107 Spring St, Washington, Seattle, 98104.
PRICE CHART FOR ATOSSA THERAPEUTICS INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$1.55
Previous Close
$1.53
Days Range
$1.51 - $1.59
52 week range
$0.60 - $2.31
Volume
1,033,879
Avg. Volume (30 days)
2,693,773
Market Cap
$191.72M
Dividend Yield
-
P/E
-
Shares Outstanding
125,304,064
Open
$1.55
Previous Close
$1.53
Days Range
$1.51 - $1.59
52 week range
$0.60 - $2.31
Volume
1,033,879
Avg. Volume (30 days)
2,693,773
Market Cap
$191.72M
Dividend Yield
-
P/E
-
Shares Outstanding
125,304,064
FINANCIAL STATEMENTS FOR ATOSSA THERAPEUTICS INC
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR ATOSSA THERAPEUTICS INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Finn Jonathan | Director | Apr 10, 2024 | Buy | $1.77 | 25,000 | 44,250 | 25,000 | Apr 11, 2024, 04:05 PM |
| WEAVER GREGORY L | Former EVP, CFO, & Director | Nov 15, 2023 | Sale | $0.65 | 50,000 | 32,500 | 55 | Nov 17, 2023, 04:01 PM |
| WEAVER GREGORY L | Director | Jul 02, 2021 | Option Exercise | $6.40 | 57,084 | 365,338 | 107,497 | Jul 07, 2021, 04:29 PM |
| WEAVER GREGORY L | Director | Jul 02, 2021 | Option Exercise | $2.22 | 164,581 | 365,337 | 164,581 | Jul 07, 2021, 04:29 PM |
| WEAVER GREGORY L | Director | Jul 02, 2021 | Sale | $5.58 | 107,497 | 599,833 | 0 | Jul 07, 2021, 04:29 PM |
| Guse Kyle | CFO, Gen Counsel and Secretary | Nov 15, 2017 | Buy | $0.34 | 10,000 | 3,369 | 10,000 | Nov 16, 2017, 06:03 AM |
| Remmel H. Lawrence | Director | Apr 17, 2017 | Buy | $0.63 | 2,500 | 1,580 | 3,126 | Apr 18, 2017, 05:10 PM |
| Remmel H. Lawrence | Director | Apr 01, 2016 | Buy | $0.33 | 1,500 | 495 | 10,900 | Apr 04, 2016, 02:02 PM |
| Chen Shu-Chih | Director | Mar 09, 2016 | Buy | $0.37 | 15,000 | 5,550 | 4,348,315 | Mar 10, 2016, 02:08 PM |
| QUAY STEVEN C | President & CEO | Mar 09, 2016 | Buy | $0.37 | 15,000 | 5,550 | 4,826,858 | Mar 10, 2016, 02:05 PM |
| QUAY STEVEN C | President & CEO | Feb 16, 2016 | Buy | $0.53 | 15,000 | 7,950 | 4,811,858 | Feb 17, 2016, 03:04 PM |
| Chen Shu-Chih | Director | Feb 16, 2016 | Buy | $0.53 | 15,000 | 7,950 | 4,333,315 | Feb 17, 2016, 03:03 PM |
| Chen Shu-Chih | Director | Jan 19, 2016 | Buy | $0.20 | 50,000 | 10,000 | 4,318,315 | Jan 21, 2016, 01:55 PM |
| QUAY STEVEN C | President & CEO | Jan 19, 2016 | Buy | $0.20 | 50,000 | 10,000 | 4,796,858 | Jan 21, 2016, 01:54 PM |
| Remmel H. Lawrence | Director | Jun 12, 2015 | Buy | $1.30 | 5,400 | 7,020 | 9,400 | Jun 15, 2015, 03:28 PM |
| WEAVER GREGORY L | Director | Nov 21, 2013 | Buy | $2.58 | 10,000 | 25,785 | 34,510 | Nov 22, 2013, 02:37 PM |
| QUAY STEVEN C | CEO | Oct 01, 2013 | Sale | $5.66 | 7,265 | 41,105 | 4,268,315 | Oct 03, 2013, 06:59 PM |
| Chen Shu-Chih | Chief Scientific Officer | Oct 01, 2013 | Sale | $5.66 | 7,265 | 41,105 | 4,268,315 | Oct 03, 2013, 06:22 PM |
| CROSS ALEXANDER D | Director | May 15, 2013 | Buy | $5.49 | 500 | 2,745 | 88,866 | Jun 27, 2013, 04:58 PM |
| Remmel H. Lawrence | Director | Jan 08, 2013 | Buy | $4.05 | 2,000 | 8,100 | 2,000 | Jan 09, 2013, 05:45 PM |
| Remmel H. Lawrence | Director | Jan 08, 2013 | Buy | $4.18 | 2,000 | 8,360 | 2,000 | Jan 09, 2013, 05:45 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Finn Jonathan | Director | 04/10/2024 | 44,250 |
| WEAVER GREGORY L | Former EVP, CFO, & Director | 11/15/2023 | 32,500 |
| WEAVER GREGORY L | Director | 07/02/2021 | 365,338 |
| WEAVER GREGORY L | Director | 07/02/2021 | 365,337 |
| WEAVER GREGORY L | Director | 07/02/2021 | 599,833 |
| Guse Kyle | CFO, Gen Counsel and Secretary | 11/15/2017 | 3,369 |
| Remmel H. Lawrence | Director | 04/17/2017 | 1,580 |
| Remmel H. Lawrence | Director | 04/01/2016 | 495 |
| Chen Shu-Chih | Director | 03/09/2016 | 5,550 |
| QUAY STEVEN C | President & CEO | 03/09/2016 | 5,550 |
| QUAY STEVEN C | President & CEO | 02/16/2016 | 7,950 |
| Chen Shu-Chih | Director | 02/16/2016 | 7,950 |
| Chen Shu-Chih | Director | 01/19/2016 | 10,000 |
| QUAY STEVEN C | President & CEO | 01/19/2016 | 10,000 |
| Remmel H. Lawrence | Director | 06/12/2015 | 7,020 |
| WEAVER GREGORY L | Director | 11/21/2013 | 25,785 |
| QUAY STEVEN C | CEO | 10/01/2013 | 41,105 |
| Chen Shu-Chih | Chief Scientific Officer | 10/01/2013 | 41,105 |
| CROSS ALEXANDER D | Director | 05/15/2013 | 2,745 |
| Remmel H. Lawrence | Director | 01/08/2013 | 8,100 |
| Remmel H. Lawrence | Director | 01/08/2013 | 8,360 |
Load More Insider Transactions
FUNDS WITH A POSITION IN ATOSSA THERAPEUTICS INC
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| BLACKROCK INC. | 2,796,437 | 0.00006% | -3.12% | Other |
| RENAISSANCE TECHNOLOGIES LLC | 1,284,270 | 0.00175% | 3.37% | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 1,114,924 | 0.0001% | 1.12% | Other |
CHANGE IN SHARES OUTSTANDING FOR ATOSSA THERAPEUTICS INC
STOCK BUYBACKS FOR ATOSSA THERAPEUTICS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
-0.40%
1Q
06/30/2023
-1.05%
2Q
03/31/2023
-1.05%
3Q
12/31/2022
-1.05%
4Q
09/30/2022
-1.05%
5Q
06/30/2022
-1.05%
6Q
03/31/2022
-1.05%
7Q
12/31/2021
-1.13%
8Q
09/30/2021
-0.98%
9Q
06/30/2021
3.06%
10Q
03/31/2021
35.33%
11Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR ATOSSA THERAPEUTICS INC
LOADING...